Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
20 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-03-01
Study Completion Date
2022-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is designed as a randomized, placebo-controlled, double-blinded, clinical trial with two parallel groups.
This study investigates the association between a single dose of the drug, Clonidine, and the total amount of opioid administered under and 24 hours after surgery in children undergoing orthopedic limb surgery with the use of tourniquet.
The investigators hypothesize that administration of clonidine to children undergoing limb surgery with the use of inflatable tourniquets would reduce post-procedural pain.
This study is a pilot to obtain an effect size. Based on this the investigators will calculate a sample size for the main trial enabling us to reach a power of 0.8 with a significans level of 0.05.
This study investigates the association between a single dose of the drug, Clonidine, and the total amount of opioid administered under and 24 hours after surgery in children undergoing orthopedic limb surgery with the use of tourniquet.
The investigators hypothesize that administration of clonidine to children undergoing limb surgery with the use of inflatable tourniquets would reduce post-procedural pain.
This study is a pilot to obtain an effect size. Based on this the investigators will calculate a sample size for the main trial enabling us to reach a power of 0.8 with a significans level of 0.05.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clonidine in Femoral Nerve Block Surgery in Children
NCT01293149
Other Reconstructive Surgery
WITHDRAWN
PHASE2
Methadone in Pediatric Anesthesia
NCT00921843
Anesthesia
COMPLETED
PHASE4
Ketorolac in Postoperative Infants: Pharmacokinetics and Safety
NCT01260883
Postoperative Pain in Infants
COMPLETED
PHASE3
The Addition of Clonidine to 0.2% Ropivacaine for Wound Instillation After Minor Lower Abdominal Surgery in Children
NCT00130091
Hernia, Inguinal
Hydrocele
COMPLETED
PHASE2
Methadone in Pediatric Anesthesiology II
NCT01990573
Pain
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Pediatric upper and lower limb surgery often requires fine tissue handling. The prevention of blood flow to a limb allows surgical procedures to be performed with improved accuracy, safety, and speed. Surgical tourniquets, compressing devices used to control venous and arterial circulation to an extremity, enable the surgeons to work in a bloodless operative field.
Tourniquet related complications comprise severe pain during and after the procedure.
In infants and children, surgical procedures are performed under general anaesthesia (GA), comprising standard analgesics and anesthesia maintenance drugs. If an inflatable tourniquet is used, supplementary opioid analgesics are often required to relieve postoperative pain. This clinical observation is in accordance with previously reported data. In adult patients, surgical extremity procedures requiring tourniquets are well known to be painful. As a consequence, infants and children are subjected to prolonged stays in the recovery department. Mobilization and referral to a more child friendly environment might be delayed.
Many interventions and different medications have been tried in order to improve postoperative analgesia in pediatric patients. Amongst these Clonidine, primarily an alpha-2 adrenoceptor agonist. Clonidine stimulates alpha-2 adrenoceptors in the brain stem, thus activating inhibitory neurons, resulting in reduced sympathetic outflow from the CNS.
In several studies' clonidine administered orally or rectally before anesthesia has shown to reduce opioid use and diminish level of pain. Additionally, clonidine reduces the occurrence of postoperative agitation. As an adjuvant to central or peripheral nerve blocks, clonidine effectively prolongs analgesia. The efficacy of clonidine has also been investigated in clinical studies with pediatric ADHD patients Tourette's syndrome and stuttering. The efficacy of Clonidine in these conditions has not been demonstrated.
Clonidine is a taste- and smell less fluid, completely opaque. Although clonidine has been widely studied in the pediatric population, the main outcome of investigations has been emergence delirium. In existing literature, the means of administration vary from intravenous, rectal, epidural or oral dosing. Intravenous single-bolus dosages range from 1.5 - 4 mcg/kg. One recent study included almost 400 patients and administered 3mcg/kg bodyweight without the occurrence of any severe events. Based on these results the investigators chose to administer 3mcg/kg bodyweight as a single bolus in our current study.
All outcomes are objective measures (mg/kg bodyweight, time endurance) or validated evaluation scales (FLACC/VAS score, PAED scale).
Morphine is widely used for postoperative pain relief, the intravenous administration being the most potent. However, morphine is known to have several side effects (prolonged sedation, nausea and vomiting, refusal of oral intake and concomitant dehydration) and may be dangerous for certain children, who experience serious respiratory depression. Hence, a reduction in total dose is crucial, especially after referral to the pediatric ward, where means of monitoring are reduced to intermittent observation and assessment of vital parameters (oxygen saturation by pulse oxymetri, heart rate and blood pressure) is only possible sporadically.
The same is true for pain and the assessment of pain using either FLACC or VAS scales.
Time-at-recovery should be held at a minimum of duration due to high turn-over in our operating facilities. Any unnecessary prolongation of recovery-time should hence be avoided.
Assessment of both primary and secondary outcomes are part of standard care and documentation of the conductance of anesthesia, recovery and post-recovery treatment at the pediatric ward. Hence, this information is readily available but will be registered in source-data sheets. After the individual participant has completed the study, the total amount of morphine administered at the pediatric ward from TREC-END to T24 will be registered by the study investigators.
Prior to any kind of scheduled surgery, patients are seen at the outpatient's clinics at the Department of Orthopedic Surgery. If the patient is less than 15 years of age and is planned for extremity surgery with the use of surgical tourniquet, the surgeon will hand out parental information material. Further, he/she will inquire, whether parents will give their accept to receive a phone call 1-3 days prior to the date of surgery. If parents approve, study investigators will contact the parents and inform them about the study.
If parents agree to study participation, a written consent form will be presented on the day of surgery by one of the study investigators for the parents to sign before induction of anesthesia. Electronic patient records will not be accessed before written consent to study participation has been granted.
All of inclusion- and exclusion criteria are readily available in every anamnesis form filled out in the electronic patient data instrument at Odense University Hospital. Since inclusion criteria comprise 'scheduled procedures', female study participants at fertile ages will hence not be pregnant, since pregnancy is a contraindication against elective/non-urgent surgery with concomitant GA.
On surgery day, children will be prepared according to departmental standard. This includes fasting for meals 6 hours and for watery drinks 1 hour prior to anaesthesia induction and premedication with sedatives at the discretion of the anaesthetist in charge. In order to reduce pre-induction anxiety, parental presence will be allowed and encouraged. Choice of inductional technique (mask or intravenous), choice of airway management device (oral tube (portex (Smiths Medical International Ltd. Bound, Kent, CT21 6JL, UK) or Ruesch (Teleflex Medical, Westmeath, Ireland)) or laryngeal mask (AmbuR AuraStraightTM, Ambu A/S, Ballerup, Denmark) and means of anaesthesia maintenance are according to anaesthetists' preference. After induction, children will receive one i.v. line (BD VenflonTM Pro, Becton Dickinson Infusion Therapy AB, Helsingborg, Sweden) and a bolus of fentanyl (Fentanyl B.Braun; B.Braun Melsungen AG, Melsungen, Tyskland) 3mcg/kg. Maintenance fluid (Ringer's Acetate, Fresenius Kabi AB, Uppsala, Sweden) will be infused at a rate of 10ml/kg the first hour and then reduced to 5ml/kg/h. Monitoring will comprise electrocardiogram (ecg), non-invasive blood pressure (NIBP), puls oxymetri, esohageal temperature (IntelliVue MP70; ViCare Medical, Birkerød, Denmark). Children will be mechanically ventilated by pressure controlled ventilation (Siesta I TS, DAMECA, Denmark) aiming at end tidal carbon dioxide (CO2) of 4.5-5.5kPa. Flow of inspiratory oxygen FiO2 will be set at 45%. Anaesthesia depth will be clinically observed and adjusted as needed. All children will receive paracetamol i.v. (Para15mg/kg after induction. As it is not departmental standard, children will not receive ondansetron or steroid for prophylaxis of post-operative nausea and vomiting (PONV).
Tourniquet will be positioned, and inflation pressure applied according to surgeons' choice. At the time of tourniquet insufflation, children will receive either an intravenous bolus of Catapressan (CatapresR Ampoules 150 micrograms in 1ml, Solution for injection, Boehringer Ingelheim Ltd., Berkshire, UK)(3mcg/kg) or an equal quantity of IV saline (Natriumklorid B.Braun 9mg/ml, B.Braun Melsungen AG, Melsungen, Tyskland). Fentanyl will be supplemented by the anaesthetist as needed according to clinical judgement.
After surgery, children will be awake extubated and transferred to recovery. In recovery, children will be observed and monitored as per departmental standard comprising pulsoxymetri and pain assessment using the FLACC score (\<6yrs) and VAS score (\>6 yrs). Presence of nausea and vomiting will be registered and treated as per departmental standard. Children will be transferred to the pediatric ward when appropriate, that is in compliance with standards. On the 1st postoperative day the total consumption of opioids 24 hours after transferral to recovery will be summed up.
Peri-anaesthetic data collection: vital parameters (pulse, mean arteria pressure in mmHg, oxygen saturation) will be recorded every 5 minutes. Total amounts in mg/kg of Propofol (intravenous maintenance) or end-tidal sevoflurane/desflurane recorded at time of incision- time of tourniquet inflation and desuflation. Level of tourniquet pressure and total time of insufflation (total-tourniquet-time) will be recorded in minutes. Total amounts of fentanyl (mcg/kg) and infused fluid (ml/kg) will be registered. Adverse events (desaturation \<90%, bradycardia and hypotension according to European Pediatric Life Support (EPLS) reference values for age) will be registered.
Recovery: FLACC/VAS score will be recorded at arrival and discharge. If pain is present during recovery, scores will be registered before and after intervention. Total amount of analgesics will be registered. Occurrence of PONV will be registered as well as interventions undertaken against. Occurrence of emergency delirium will be registered. Time-to-discharge will be registered (in minutes).
Children will be transferred to the pediatric ward when appropriate, that is in compliance with standards. On the 1st postoperative day the total consumption of opioids 24 hours after transferral to recovery will be summed up.
The investigators chose the parallel-group design for the CLOTCH-Study. In accordance with ICH-GCP recommendations on statistical principles for clinical trials (E9), the primary analyses will be differences in primary and secondary outcomes adjusted for stratification variables (i.e. means of anaesthesia maintenance (TIVA or Inhalational), tourniquet-time and tourniquet pressure level, age groups \<1year, 1-6years, \>6years). The investigators will assess and report all outcomes as "intention-to-treat" analysis including all randomised children meeting the inclusion criteria and not fulfilling the exclusion criteria with a standing consent to participate. Complete case analysis will be carried out if the overall level of missing data is less than 5%. However, if exceeding the limit of 5% missing data and if Littles' test is statistically significant, multiple imputation will be used and considered the primary result of the trial to reduce bias from complete case analysis. Little's test tests the null hypothesis that the missing data is Missing Completely At Random (MCAR). A p-value of less than 0.05 is usually interpreted as being that the missing data is not MCAR (i.e. is either Missing At Random or non-ignorable). The investigators will present "worst-case" and "best-case" scenarios. p \< 0.05 will be considered statistically significant. For each group, all children will be analysed for the primary outcome. For each primary and secondary outcome, the results and estimated effect sizes with 95% confidence interval will be provided. The investigators will exclude patients with major protocol violations defined as failure to receive the total drug dose. The investigators will carry out statistical analyses before revealing the code of allocation.
The trial offers benefits for the population, which the minor study participant represents. These comprise
* Improved strategies for treatment of pain after use of surgical tourniquets for extremity surgery
* Reduced anxiety and discomfort postoperatively due to reduced pain levels
* Accelerated mobilization postoperatively - a major factor in order to prevent immobility related complications (pulmonary infections, obstipation)
* Reduced-time-to-oral-intake, which is extremely important in all age groups, but crucial for infants, who have a high metabolism and hence are at high risk of complications due to anaerobic energy production.
Tourniquet related complications comprise severe pain during and after the procedure.
In infants and children, surgical procedures are performed under general anaesthesia (GA), comprising standard analgesics and anesthesia maintenance drugs. If an inflatable tourniquet is used, supplementary opioid analgesics are often required to relieve postoperative pain. This clinical observation is in accordance with previously reported data. In adult patients, surgical extremity procedures requiring tourniquets are well known to be painful. As a consequence, infants and children are subjected to prolonged stays in the recovery department. Mobilization and referral to a more child friendly environment might be delayed.
Many interventions and different medications have been tried in order to improve postoperative analgesia in pediatric patients. Amongst these Clonidine, primarily an alpha-2 adrenoceptor agonist. Clonidine stimulates alpha-2 adrenoceptors in the brain stem, thus activating inhibitory neurons, resulting in reduced sympathetic outflow from the CNS.
In several studies' clonidine administered orally or rectally before anesthesia has shown to reduce opioid use and diminish level of pain. Additionally, clonidine reduces the occurrence of postoperative agitation. As an adjuvant to central or peripheral nerve blocks, clonidine effectively prolongs analgesia. The efficacy of clonidine has also been investigated in clinical studies with pediatric ADHD patients Tourette's syndrome and stuttering. The efficacy of Clonidine in these conditions has not been demonstrated.
Clonidine is a taste- and smell less fluid, completely opaque. Although clonidine has been widely studied in the pediatric population, the main outcome of investigations has been emergence delirium. In existing literature, the means of administration vary from intravenous, rectal, epidural or oral dosing. Intravenous single-bolus dosages range from 1.5 - 4 mcg/kg. One recent study included almost 400 patients and administered 3mcg/kg bodyweight without the occurrence of any severe events. Based on these results the investigators chose to administer 3mcg/kg bodyweight as a single bolus in our current study.
All outcomes are objective measures (mg/kg bodyweight, time endurance) or validated evaluation scales (FLACC/VAS score, PAED scale).
Morphine is widely used for postoperative pain relief, the intravenous administration being the most potent. However, morphine is known to have several side effects (prolonged sedation, nausea and vomiting, refusal of oral intake and concomitant dehydration) and may be dangerous for certain children, who experience serious respiratory depression. Hence, a reduction in total dose is crucial, especially after referral to the pediatric ward, where means of monitoring are reduced to intermittent observation and assessment of vital parameters (oxygen saturation by pulse oxymetri, heart rate and blood pressure) is only possible sporadically.
The same is true for pain and the assessment of pain using either FLACC or VAS scales.
Time-at-recovery should be held at a minimum of duration due to high turn-over in our operating facilities. Any unnecessary prolongation of recovery-time should hence be avoided.
Assessment of both primary and secondary outcomes are part of standard care and documentation of the conductance of anesthesia, recovery and post-recovery treatment at the pediatric ward. Hence, this information is readily available but will be registered in source-data sheets. After the individual participant has completed the study, the total amount of morphine administered at the pediatric ward from TREC-END to T24 will be registered by the study investigators.
Prior to any kind of scheduled surgery, patients are seen at the outpatient's clinics at the Department of Orthopedic Surgery. If the patient is less than 15 years of age and is planned for extremity surgery with the use of surgical tourniquet, the surgeon will hand out parental information material. Further, he/she will inquire, whether parents will give their accept to receive a phone call 1-3 days prior to the date of surgery. If parents approve, study investigators will contact the parents and inform them about the study.
If parents agree to study participation, a written consent form will be presented on the day of surgery by one of the study investigators for the parents to sign before induction of anesthesia. Electronic patient records will not be accessed before written consent to study participation has been granted.
All of inclusion- and exclusion criteria are readily available in every anamnesis form filled out in the electronic patient data instrument at Odense University Hospital. Since inclusion criteria comprise 'scheduled procedures', female study participants at fertile ages will hence not be pregnant, since pregnancy is a contraindication against elective/non-urgent surgery with concomitant GA.
On surgery day, children will be prepared according to departmental standard. This includes fasting for meals 6 hours and for watery drinks 1 hour prior to anaesthesia induction and premedication with sedatives at the discretion of the anaesthetist in charge. In order to reduce pre-induction anxiety, parental presence will be allowed and encouraged. Choice of inductional technique (mask or intravenous), choice of airway management device (oral tube (portex (Smiths Medical International Ltd. Bound, Kent, CT21 6JL, UK) or Ruesch (Teleflex Medical, Westmeath, Ireland)) or laryngeal mask (AmbuR AuraStraightTM, Ambu A/S, Ballerup, Denmark) and means of anaesthesia maintenance are according to anaesthetists' preference. After induction, children will receive one i.v. line (BD VenflonTM Pro, Becton Dickinson Infusion Therapy AB, Helsingborg, Sweden) and a bolus of fentanyl (Fentanyl B.Braun; B.Braun Melsungen AG, Melsungen, Tyskland) 3mcg/kg. Maintenance fluid (Ringer's Acetate, Fresenius Kabi AB, Uppsala, Sweden) will be infused at a rate of 10ml/kg the first hour and then reduced to 5ml/kg/h. Monitoring will comprise electrocardiogram (ecg), non-invasive blood pressure (NIBP), puls oxymetri, esohageal temperature (IntelliVue MP70; ViCare Medical, Birkerød, Denmark). Children will be mechanically ventilated by pressure controlled ventilation (Siesta I TS, DAMECA, Denmark) aiming at end tidal carbon dioxide (CO2) of 4.5-5.5kPa. Flow of inspiratory oxygen FiO2 will be set at 45%. Anaesthesia depth will be clinically observed and adjusted as needed. All children will receive paracetamol i.v. (Para15mg/kg after induction. As it is not departmental standard, children will not receive ondansetron or steroid for prophylaxis of post-operative nausea and vomiting (PONV).
Tourniquet will be positioned, and inflation pressure applied according to surgeons' choice. At the time of tourniquet insufflation, children will receive either an intravenous bolus of Catapressan (CatapresR Ampoules 150 micrograms in 1ml, Solution for injection, Boehringer Ingelheim Ltd., Berkshire, UK)(3mcg/kg) or an equal quantity of IV saline (Natriumklorid B.Braun 9mg/ml, B.Braun Melsungen AG, Melsungen, Tyskland). Fentanyl will be supplemented by the anaesthetist as needed according to clinical judgement.
After surgery, children will be awake extubated and transferred to recovery. In recovery, children will be observed and monitored as per departmental standard comprising pulsoxymetri and pain assessment using the FLACC score (\<6yrs) and VAS score (\>6 yrs). Presence of nausea and vomiting will be registered and treated as per departmental standard. Children will be transferred to the pediatric ward when appropriate, that is in compliance with standards. On the 1st postoperative day the total consumption of opioids 24 hours after transferral to recovery will be summed up.
Peri-anaesthetic data collection: vital parameters (pulse, mean arteria pressure in mmHg, oxygen saturation) will be recorded every 5 minutes. Total amounts in mg/kg of Propofol (intravenous maintenance) or end-tidal sevoflurane/desflurane recorded at time of incision- time of tourniquet inflation and desuflation. Level of tourniquet pressure and total time of insufflation (total-tourniquet-time) will be recorded in minutes. Total amounts of fentanyl (mcg/kg) and infused fluid (ml/kg) will be registered. Adverse events (desaturation \<90%, bradycardia and hypotension according to European Pediatric Life Support (EPLS) reference values for age) will be registered.
Recovery: FLACC/VAS score will be recorded at arrival and discharge. If pain is present during recovery, scores will be registered before and after intervention. Total amount of analgesics will be registered. Occurrence of PONV will be registered as well as interventions undertaken against. Occurrence of emergency delirium will be registered. Time-to-discharge will be registered (in minutes).
Children will be transferred to the pediatric ward when appropriate, that is in compliance with standards. On the 1st postoperative day the total consumption of opioids 24 hours after transferral to recovery will be summed up.
The investigators chose the parallel-group design for the CLOTCH-Study. In accordance with ICH-GCP recommendations on statistical principles for clinical trials (E9), the primary analyses will be differences in primary and secondary outcomes adjusted for stratification variables (i.e. means of anaesthesia maintenance (TIVA or Inhalational), tourniquet-time and tourniquet pressure level, age groups \<1year, 1-6years, \>6years). The investigators will assess and report all outcomes as "intention-to-treat" analysis including all randomised children meeting the inclusion criteria and not fulfilling the exclusion criteria with a standing consent to participate. Complete case analysis will be carried out if the overall level of missing data is less than 5%. However, if exceeding the limit of 5% missing data and if Littles' test is statistically significant, multiple imputation will be used and considered the primary result of the trial to reduce bias from complete case analysis. Little's test tests the null hypothesis that the missing data is Missing Completely At Random (MCAR). A p-value of less than 0.05 is usually interpreted as being that the missing data is not MCAR (i.e. is either Missing At Random or non-ignorable). The investigators will present "worst-case" and "best-case" scenarios. p \< 0.05 will be considered statistically significant. For each group, all children will be analysed for the primary outcome. For each primary and secondary outcome, the results and estimated effect sizes with 95% confidence interval will be provided. The investigators will exclude patients with major protocol violations defined as failure to receive the total drug dose. The investigators will carry out statistical analyses before revealing the code of allocation.
The trial offers benefits for the population, which the minor study participant represents. These comprise
* Improved strategies for treatment of pain after use of surgical tourniquets for extremity surgery
* Reduced anxiety and discomfort postoperatively due to reduced pain levels
* Accelerated mobilization postoperatively - a major factor in order to prevent immobility related complications (pulmonary infections, obstipation)
* Reduced-time-to-oral-intake, which is extremely important in all age groups, but crucial for infants, who have a high metabolism and hence are at high risk of complications due to anaerobic energy production.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Polydactyly Toe
Thumb Hypoplasia
Trigger Finger
Polydactyly; Fingers
Osteomyelitis of Hindfoot
Osteomyelitis of Midfoot
Congenital Talipes Equinovarus
Congenital Talipes Calcaneus
Tarsal Coalition
Club Foot
Clubfoot
Congenital Knee Deformity
Leg Length Inequality in Children
Flatfoot
Hollow Foot
Congenital Valgus Foot Deformity
Polydactylia
Polysyndactyly
Syndactyly
Thumb Aplasia
Congenital Hand and Foot Deformity
Subungual Exostosis
Finger Deformity
Toe Deformity
Osteomyelitis of the Foot
Calcaneus Deformity of Foot
Congenital Hand Deformity
Hand Deformities, Congenital
Valgus Foot Deformity
Toe Joint Deformity
Capsulitis of MTP Joint
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
SUPPORTIVE_CARE
Blinding Strategy
TRIPLE
Participants
Caregivers
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
IV Saline (Natriumklorid B.Braun 9mg/ml, B.Braun Melsungen AG, Melsungen, Tyskland) in an equal quantity as the study drug is administered at tourniquet inflation
Group Type
PLACEBO_COMPARATOR
Saline
Intervention Type
OTHER
controlgroup receiving saline
Intervention group
Catapressan (CatapresR Ampoules 150 micrograms in 1ml, Solution for injection, Boehringer Ingelheim Ltd., Berkshire, UK)(3mcg/kg) is administered at tourniquet inflation
Group Type
EXPERIMENTAL
Catapresan
Intervention Type
DRUG
The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Catapresan
The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.
Intervention Type
DRUG
Saline
controlgroup receiving saline
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Clonidine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA I + II
* Scheduled for GA and planned for relevant surgical procedure (according to table 1)
* Planned use of surgical tourniquet on upper and/or lower extremity
* Scheduled for GA and planned for relevant surgical procedure (according to table 1)
* Planned use of surgical tourniquet on upper and/or lower extremity
Exclusion Criteria
* parental consent missing
* ASA classification \>II
* Known diagnosis of QT-prolongation syndrome
* known allergies to clonidine
* known allergies or intolerance to morphine
* daily use of pain killers
* under treatment with antihypertensive and antiarrythmic medications
* status of current or previous prematurity
* planned for peripheral or central nerve block in addition to general anaesthesia
* ASA classification \>II
* Known diagnosis of QT-prolongation syndrome
* known allergies to clonidine
* known allergies or intolerance to morphine
* daily use of pain killers
* under treatment with antihypertensive and antiarrythmic medications
* status of current or previous prematurity
* planned for peripheral or central nerve block in addition to general anaesthesia
Minimum Eligible Age
3 Months
Maximum Eligible Age
15 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Odense Patient Data Explorative Network
OTHER
Sponsor Role
collaborator
Odense University Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nicola Groes Clausen
Principle Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicola G. Clausen, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Anaesthesiology and Intensive Care at Odense University Hospital
Tom G. Hansen, Ph.D.
Role: STUDY_DIRECTOR
Department of Anaesthesiology and Intensive Care at Odense University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Odense University Hospital
Odense, Fyn, Denmark
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Denmark
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Budic I, Pavlovic D, Kitic D, Kocic G, Cvetkovic T, Simic D, Jevtovic-Stoimenov T. Tourniquet-induced ischemia-reperfusion injuries during extremity surgery at children's age: impact of anesthetic chemical structure. Redox Rep. 2013;18(1):20-6. doi: 10.1179/1351000212Y.0000000037.
Reference Type
BACKGROUND
Kumar K, Railton C, Tawfic Q. Tourniquet application during anesthesia: "What we need to know?". J Anaesthesiol Clin Pharmacol. 2016 Oct-Dec;32(4):424-430. doi: 10.4103/0970-9185.168174.
Reference Type
BACKGROUND
Kruse H, Christensen KP, Moller AM, Gogenur I. Tourniquet use during ankle surgery leads to increased postoperative opioid use. J Clin Anesth. 2015 Aug;27(5):380-4. doi: 10.1016/j.jclinane.2015.03.034. Epub 2015 May 12.
Reference Type
BACKGROUND
Rudkin AK, Rudkin GE, Dracopoulos GC. Acceptability of ankle tourniquet use in midfoot and forefoot surgery: audit of 1000 cases. Foot Ankle Int. 2004 Nov;25(11):788-94. doi: 10.1177/107110070402501106.
Reference Type
BACKGROUND
Budic I, Pavlovic D, Kocic G, Cvetkovic T, Simic D, Basic J, Zivanovic D. Biomarkers of oxidative stress and endothelial dysfunction after tourniquet release in children. Physiol Res. 2011;60(Suppl 1):S137-45. doi: 10.33549/physiolres.932170. Epub 2011 Jul 19.
Reference Type
BACKGROUND
Estebe JP, Davies JM, Richebe P. The pneumatic tourniquet: mechanical, ischaemia-reperfusion and systemic effects. Eur J Anaesthesiol. 2011 Jun;28(6):404-11. doi: 10.1097/EJA.0b013e328346d5a9.
Reference Type
BACKGROUND
Gourdin M, Dubois P, Mullier F, Chatelain B, Dogne JM, Marchandise B, Jamart J, De Kock M. The effect of clonidine, an alpha-2 adrenergic receptor agonist, on inflammatory response and postischemic endothelium function during early reperfusion in healthy volunteers. J Cardiovasc Pharmacol. 2012 Dec;60(6):553-60. doi: 10.1097/FJC.0b013e31827303fa.
Reference Type
BACKGROUND
Jellinge ME, Petersen RH. [Clonidine can reduce opioid medication during post-operative pain]. Ugeskr Laeger. 2015 Nov 30;177(49):V05150415. Danish.
Reference Type
BACKGROUND
Isaac L. Clonidine in the central nervous system: site and mechanism of hypotensive action. J Cardiovasc Pharmacol. 1980;2 Suppl 1:S5-19.
Reference Type
BACKGROUND
Ydemann M, Nielsen BN, Wetterslev J, Henneberg S, Lauritsen T, Steen N, Edstrom B, Afshari A. Effect of clonidine to prevent agitation in children after sevoflurane anaesthesia: a randomised placebo controlled multicentre trial. Dan Med J. 2016 Jun;63(6):A5234.
Reference Type
BACKGROUND
Lambert P, Cyna AM, Knight N, Middleton P. Clonidine premedication for postoperative analgesia in children. Cochrane Database Syst Rev. 2014 Jan 28;2014(1):CD009633. doi: 10.1002/14651858.CD009633.pub2.
Reference Type
BACKGROUND
Boric K, Dosenovic S, Jelicic Kadic A, Batinic M, Cavar M, Urlic M, Markovina N, Puljak L. Interventions for postoperative pain in children: An overview of systematic reviews. Paediatr Anaesth. 2017 Sep;27(9):893-904. doi: 10.1111/pan.13203. Epub 2017 Jul 14.
Reference Type
BACKGROUND
Wang W, Huang P, Gao W, Cao F, Yi M, Chen L, Guo X. Efficacy and Acceptability of Different Auxiliary Drugs in Pediatric Sevoflurane Anesthesia: A Network Meta-analysis of Mixed Treatment Comparisons. Sci Rep. 2016 Nov 10;6:36553. doi: 10.1038/srep36553.
Reference Type
BACKGROUND
Moore AD, Anghelescu DL. Emergence Delirium in Pediatric Anesthesia. Paediatr Drugs. 2017 Feb;19(1):11-20. doi: 10.1007/s40272-016-0201-5.
Reference Type
BACKGROUND
Afshari A. Clonidine in pediatric anesthesia: the new panacea or a drug still looking for an indication? Curr Opin Anaesthesiol. 2019 Jun;32(3):327-333. doi: 10.1097/ACO.0000000000000724.
Reference Type
BACKGROUND
Ydemann M, Nielsen BN, Henneberg S, Jakobsen JC, Wetterslev J, Lauritsen T, Steen N, Edstrom B, Afshari A; PREVENT AGITATION Research Group. Intraoperative clonidine for prevention of postoperative agitation in children anaesthetised with sevoflurane (PREVENT AGITATION): a randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health. 2018 Jan;2(1):15-24. doi: 10.1016/S2352-4642(17)30127-X. Epub 2017 Nov 2.
Reference Type
BACKGROUND
Khetani JD, Madadi P, Sommer DD, Reddy D, Sistonen J, Ross CJ, Carleton BC, Hayden MR, Koren G. Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome: a prospective pilot study. Paediatr Drugs. 2012 Dec 1;14(6):411-5. doi: 10.2165/11633570-000000000-00000.
Reference Type
BACKGROUND
Kelly LE, Sommer DD, Ramakrishna J, Hoffbauer S, Arbab-Tafti S, Reid D, Maclean J, Koren G. Morphine or Ibuprofen for post-tonsillectomy analgesia: a randomized trial. Pediatrics. 2015 Feb;135(2):307-13. doi: 10.1542/peds.2014-1906.
Reference Type
BACKGROUND
Jay MA, Thomas BM, Nandi R, Howard RF. Higher risk of opioid-induced respiratory depression in children with neurodevelopmental disability: a retrospective cohort study of 12 904 patients. Br J Anaesth. 2017 Feb;118(2):239-246. doi: 10.1093/bja/aew403.
Reference Type
BACKGROUND
Oderda GM, Senagore AJ, Morland K, Iqbal SU, Kugel M, Liu S, Habib AS. Opioid-related respiratory and gastrointestinal adverse events in patients with acute postoperative pain: prevalence, predictors, and burden. J Pain Palliat Care Pharmacother. 2019 Sep-Dec;33(3-4):82-97. doi: 10.1080/15360288.2019.1668902. Epub 2019 Oct 14.
Reference Type
BACKGROUND
Berghmans JM, Poley MJ, van der Ende J, Weber F, Van de Velde M, Adriaenssens P, Himpe D, Verhulst FC, Utens E. A Visual Analog Scale to assess anxiety in children during anesthesia induction (VAS-I): Results supporting its validity in a sample of day care surgery patients. Paediatr Anaesth. 2017 Sep;27(9):955-961. doi: 10.1111/pan.13206. Epub 2017 Jul 14.
Reference Type
BACKGROUND
Malviya S, Voepel-Lewis T, Burke C, Merkel S, Tait AR. The revised FLACC observational pain tool: improved reliability and validity for pain assessment in children with cognitive impairment. Paediatr Anaesth. 2006 Mar;16(3):258-65. doi: 10.1111/j.1460-9592.2005.01773.x.
Reference Type
BACKGROUND
Pedersen LK, Rahbek O, Nikolajsen L, Moller-Madsen B. The revised FLACC score: Reliability and validation for pain assessment in children with cerebral palsy. Scand J Pain. 2015 Oct 1;9(1):57-61. doi: 10.1016/j.sjpain.2015.06.007.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NC12547
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Clonidine for Infra-orbital Nerve Block During Pediatric Cleft Lip Revision Surgeries
NCT05790044
UNKNOWN
NA
The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children
NCT00580151
TERMINATED
NA
Double Blind Randomized Study Into the Efficacy of Codeine Phosphate Analgesia After Cleft Palate Repair in Infants
NCT00386269
COMPLETED
PHASE4
Opioid Laws and Pediatric Use
NCT04543227
COMPLETED
Clonidine as Pain Relief During ROP Eye Examinations
NCT04902859
UNKNOWN
PHASE4
Randomized, Double-blind, Placebo, Controlled Cross Over Design Topical Morphine for Analgesia in Pediatric Procedures
NCT02300194
WITHDRAWN
PHASE4
Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery
NCT01812044
COMPLETED
NA
Morphine PK Subgroup Analysis
NCT01322191
COMPLETED
PHASE4
Anesthetics and Analgesics in Children
NCT03427736
RECRUITING
Parental Perceptions on Prescription Opioid Use
NCT05344118
COMPLETED
The Effect of General Anesthesia on Pharmacokinetics of Oxycodone in Pediatric
NCT03054831
RECRUITING
PHASE4
Pain Medications in Children Undergoing Strabismus Surgery
NCT02789969
UNKNOWN
NA
Distraction for Reduction of Pain Associated With Venipuncture in the Pediatric Post-Transplant Population
NCT03004456
COMPLETED
NA
Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries
NCT04523623
WITHDRAWN
NA
Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects
NCT02687451
TERMINATED
PHASE3
Efficacy, Safety and Pharmacokinetic Study of Intravenous Clonidine Versus Midazolam for Sedation in Paediatric Patients
NCT02509273
TERMINATED
PHASE3
Transversus Abdominis Plane Blocks for Infants and Children for Postoperative Pain Control
NCT01559740
COMPLETED
PHASE2
Morphine or Ketamine for Analgesia
NCT06835504
NOT_YET_RECRUITING
PHASE3
Hypnoanalgesia for Dermatological Surgery in Children
NCT04707014
COMPLETED
NA
Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia
NCT01325493
COMPLETED
PHASE4
Study to Find the Dose of Rapidly Administered Ketamine for Brief Painful Procedures in Children
NCT01669642
COMPLETED
NA
The Efficacy and Safety of Chloroprocaine 1% and 2% in Pediatric Population
NCT03918798
RECRUITING
PHASE2
Clinical Study of Caffeine for Apnea of Prematurity
NCT01408173
COMPLETED
PHASE3
The Effect of Pain Medication in Children With Acute Abdominal Pain and Its Implication Over the Surgeon's Decision
NCT00839787
WITHDRAWN
NA
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
NCT02044497
RECRUITING
PHASE4